OncLive TV

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, talks about the interaction between estrogen receptors (ER) and androgen receptors (AR) in patients with breast cancer.

Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.

Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, explains how nurses in her practice discuss genetics and genomics with patients.

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes the Prostate Health Cocktail.

Donna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Associate Professor, Department of Medicine, Harvard Medical School, discusses using technology to communicate with patients

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor (CAR)–modified T cells when used to treat B-cell malignancies.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, discusses the results of the AVAPERL trial.

Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.

Everett E. Vokes, MD, Giant of Cancer Care in the Head and Neck Cancer Category, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses HPV-related head and neck cancer

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses reducing neurotoxicity in small cell lung cancer patients.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Jennifer Woyach, MD, discusses peripheral lymphocytosis in patients with chronic lymphocytic leukemia after they take ibrutinib.

Harvey I. Pass, MD, from the NYU Langone Medical Center, discusses the challenges of treating patients with mesothelioma.

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.

Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Gail Eckhardt, MD, from the University of Colorado Denver and Health Sciences Center, discusses the future role of aflibercept for patients with metastatic colorectal cancer.

Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the treatment of older patients with acute myeloid leukemia (AML).

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Bonnie Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), discusses support groups for patients with lung cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the future of antibodies, including nivolumab, for the treatment of lung cancer.